PATENT AND KNOW-HOW EXCLUSIVE SUBLICENSE AGREEMENT BY AND AMONG IMMUNODEX, INC. AND SOMANTA LIMITEDPatent and Know-How Exclusive Sublicense Agreement • February 6th, 2006 • Somanta Pharmaceuticals Inc. • Optical instruments & lenses • California
SIDE AMENDMENT TO PATENT AND KNOW-HOW EXCLUSIVE SUBLICENSE AGREEMENTPatent and Know-How Exclusive Sublicense Agreement • December 11th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations
This Side Amendment to patent and know-how exclusive sublicense Agreement (the “Side Agreement”) is entered into Friday, November 3, 2006 (“Effective Date”) by and among Immunodex, Inc., a California corporation having an address at 1230 H Street, Eureka, California, 95501 (“Immunodex”); The Cancer Research Institute of Contra Costa having an address at 1230 H Street, Eureka, CA 95501 (“CRICC”); and Somanta Incorporated (“Somanta”) having business addresses at 19200 Von Karman Avenue, Suite 400, Irvine, CA 92612 USA and 80 Harley Street, London, W1G 7HB, United Kingdom.
SECOND SIDE AMENDMENT TO PATENT AND KNOW-HOW EXCLUSVE SUBLICENSE AGREEMENT DATED AUGUST 18, 2005 AND ITS SIDE AMENDMENT DATED NOVEMBER 3, 2006.Patent and Know-How Exclusive Sublicense Agreement • March 19th, 2007 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations
This Second Side Amendment to patent and know-how exclusive sublicense Agreement (dated 8/18/05) (Sublicense Agreement) and its Side Amendment (dated 11/3/06) (Side Amendment) is entered into Wednesday, January 18, 2007 by Immunodex, a California corporation in Eureka, California (Immunodex) and Somanta Incorporated having business offices in Irvine, California and London, United Kingdom (Somanta).
ContractPatent and Know-How Exclusive Sublicense Agreement • July 19th, 2006 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations • California
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24(b)(2) OF THE SECURITIES AND EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT IS REQUESTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT REQUESTED].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
